dc.contributor.author | Feliú Batlle, Jaime | |
dc.contributor.author | Safont, María José | |
dc.contributor.author | Salud, Antonieta T. | |
dc.contributor.author | Losa, Ferrán C. | |
dc.contributor.author | García-Girón, Carlos | |
dc.contributor.author | Bosch, Carles J A | |
dc.contributor.author | Escudero, Pilar | |
dc.contributor.author | López Manzanera, Rafael | |
dc.contributor.author | Madroñal, C. | |
dc.contributor.author | Bolaños, Margarita | |
dc.contributor.author | Gil, Mireia | |
dc.contributor.author | Llombart, Antonio C. | |
dc.contributor.author | Castro-Carpeño, J. | |
dc.contributor.author | González Barón, Manuel | |
dc.contributor.other | UAM. Departamento de Medicina | es_ES |
dc.date.accessioned | 2014-11-04T10:58:00Z | |
dc.date.available | 2014-11-04T10:58:00Z | |
dc.date.issued | 2010-05-01 | |
dc.identifier.citation | British Journal of Cancer 102.10 (2010): 1468 – 1473 | en_US |
dc.identifier.issn | 0007-0920 (print) | en_US |
dc.identifier.issn | 1532-1827 (online) | en_US |
dc.identifier.uri | http://hdl.handle.net/10486/662397 | |
dc.description.abstract | BACKGROUND: The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC)
considered unsuitable for receiving first-line chemotherapy with an irinotecan or oxaliplatin-based combination were assessed in a
phase II, open, multicentre, uncontrolled study.
METHODS: Treatment consisted of capecitabine 1250 mgm 2 (or 950 mgm 2 for patients with a creatinine clearance of
30–50ml min 1) twice daily on days 1–14 and bevacizumab (7.5 mg kg 1) on day 1 every 3 weeks.
RESULTS: A total of 59 patients aged X70 years with mCRC were enrolled. In an intention-to-treat analysis, the overall response rate
was 34%, with 71% of patients achieving disease control. Median progression-free survival and overall survival were 10.8 months and
18 months, respectively. In all, 32 patients (54%) had grade 3/4 adverse events (AEs), the most common being hand–foot syndrome
(19%), diarrhoea (9%) and deep venous thrombosis (7%). Four patients died because of treatment-related AEs. A relationship was
detected between creatinine clearance p50 ml min 1 and the development of non-bevacizumab-related grade 3/4 AEs. The
incidence of bevacizumab-associated AEs (hypertension, thromboembolic events and proteinuria) was consistent with that of
previous reports in elderly patients.
CONCLUSION: Bevacizumab combined with capecitabine represents a valid therapeutic alternative in elderly patients considered to be
unsuitable for receiving polychemotherapy. | en_US |
dc.description.sponsorship | This study was supported by Hoffmann-La Roche, Nutley, NJ,
USA. | en_US |
dc.format.extent | 6 pag. | en |
dc.format.mimetype | application/pdf | en |
dc.language.iso | eng | en |
dc.publisher | Nature Publishing Group | en_US |
dc.relation.ispartof | British journal of cancer | en_US |
dc.rights | © 2010 Cancer Research UK | en_US |
dc.subject.other | Aged | en_US |
dc.subject.other | Bevacizumab | en_US |
dc.subject.other | Capecitabine | en_US |
dc.subject.other | Colorectal neoplasms | en_US |
dc.subject.other | Neoplasm metastasis | en_US |
dc.title | Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer | en_US |
dc.type | article | en |
dc.subject.eciencia | Medicina | es_ES |
dc.relation.publisherversion | http://dx.doi.org/10.1038/sj.bjc.6605663 | es_ES |
dc.identifier.doi | 10.1038/sj.bjc.6605663 | es_ES |
dc.identifier.publicationfirstpage | 1468 | es_ES |
dc.identifier.publicationissue | 10 | es_ES |
dc.identifier.publicationlastpage | 1473 | es_ES |
dc.identifier.publicationvolume | 102 | es_ES |
dc.type.version | info:eu-repo/semantics/publishedVersion | en |
dc.rights.cc | © 2010 Cancer Research UK | en_US |
dc.rights.accessRights | openAccess | en |
dc.authorUAM | Feliú Batlle, Jaime (261277) | |
dc.authorUAM | González Barón, Manuel (259851) | |
dc.facultadUAM | Facultad de Medicina | |
dc.institutoUAM | Instituto de Investigación Sanitaria Hospital Universitario de La Paz (IdiPAZ) | |